98 related articles for article (PubMed ID: 7769797)
41. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
Kleinbloesem CH; Weber C; Fahrner E; Dellenbach M; Welker H; Schröter V; Belz GG
Clin Pharmacol Ther; 1993 May; 53(5):585-92. PubMed ID: 8491068
[TBL] [Abstract][Full Text] [Related]
42. Comparative studies on differential inhibition of the renin - angiotensin system in the anesthetized guinea pig.
Duan J; Jaramillo J; Jung GL; McLeod AL; Fernandes BH; Mathis D
Can J Physiol Pharmacol; 1995 Oct; 73(10):1512-8. PubMed ID: 8748944
[TBL] [Abstract][Full Text] [Related]
43. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
Christen Y; Waeber B; Nussberger J; Porchet M; Borland RM; Lee RJ; Maggon K; Shum L; Timmermans PB; Brunner HR
Circulation; 1991 Apr; 83(4):1333-42. PubMed ID: 2013151
[TBL] [Abstract][Full Text] [Related]
44. Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in nonhuman primates.
DeGraaf GL; Pals DT; Couch SJ; Lawson JA
J Pharmacol Exp Ther; 1993 Jan; 264(1):6-10. PubMed ID: 8423551
[TBL] [Abstract][Full Text] [Related]
45. Renal function in one-kidney, one clip sodium-restricted rats: influence of enalapril and losartan.
Demeilliers B; Jover B; Mimran A
J Hypertens; 1995 Dec; 13(12 Pt 2):1764-6. PubMed ID: 8903648
[TBL] [Abstract][Full Text] [Related]
46. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans.
Gandhi SK; Ryder DH; Brown NJ
Hypertension; 1996 Dec; 28(6):961-6. PubMed ID: 8952583
[TBL] [Abstract][Full Text] [Related]
47. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
Buter H; Hemmelder MH; van Paassen P; Navis G; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1997; 12 Suppl 2():53-6. PubMed ID: 9269701
[TBL] [Abstract][Full Text] [Related]
48. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
49. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
50. The advantages of angiotensin II antagonism.
Burnier M; Waeber B; Brunner HR
J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
[TBL] [Abstract][Full Text] [Related]
51. Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man.
MacFadyen RJ; Elliott HL; Meredith PA; Reid JL
Br J Clin Pharmacol; 1993 Mar; 35(3):299-301. PubMed ID: 8471406
[TBL] [Abstract][Full Text] [Related]
52. Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs.
el Amrani AI; Menard J; Gonzales MF; Michel JB
J Cardiovasc Pharmacol; 1993 Aug; 22(2):231-9. PubMed ID: 7692163
[TBL] [Abstract][Full Text] [Related]
53. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
Hagino T; Abe K; Tsunoda K; Yoshinaga K
Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
[TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
Sweet CS; Bradstreet DC; Berman RS; Jallard N; Saenz A; Weidler DJ
Am J Hypertens; 1994 Dec; 7(12):1035-40. PubMed ID: 7702795
[TBL] [Abstract][Full Text] [Related]
55. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
[TBL] [Abstract][Full Text] [Related]
56. Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats.
Mizuno K; Niimura S; Tani M; Haga H; Gomibuchi T; Sanada H; Fukuchi S
Eur J Pharmacol; 1992 May; 215(2-3):305-8. PubMed ID: 1396995
[TBL] [Abstract][Full Text] [Related]
57. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
Burdmann EA; Andoh TF; Nast CC; Evan A; Connors BA; Coffman TM; Lindsley J; Bennett WM
Am J Physiol; 1995 Oct; 269(4 Pt 2):F491-9. PubMed ID: 7485533
[TBL] [Abstract][Full Text] [Related]
58. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Major TC; Olszewski B; Rosebury W; Okerberg C; Carlson T; Ostroski R; Schroeder R; Kowala MC; Leadley R
Cardiovasc Drugs Ther; 2008 Dec; 22(6):469-78. PubMed ID: 18679781
[TBL] [Abstract][Full Text] [Related]
59. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
Ruzicka M; Yuan B; Harmsen E; Leenen FH
Circulation; 1993 Mar; 87(3):921-30. PubMed ID: 8443912
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin II receptor antagonists: the prototype losartan.
Schaefer KL; Porter JA
Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
